Cholinergic connectivity: It's implications for psychiatric disorders

Frontiers in Cellular Neuroscience

Volumn , Issue APR, 2013, Pages

  Scarr, Elizabeth ^a,b   Gibbons, Andrew Stuart ^a,b   Neo, Jaclyn ^a,b   Udawela, Madhara ^a,b   Dean, Brian ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Acetylcholine; Cytokines; Dopamine; GABA; Glutamate; Psychiatric disorders; Serotonin

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; DOPAMINE; GLUTAMIC ACID; SEROTONIN;

4 AMINOBUTYRIC ACID RELEASE; ACETYLCHOLINE RELEASE; CHOLINERGIC SYSTEM; CHOLINERGIC TRANSMISSION; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; LONG TERM POTENTIATION; MENTAL DISEASE; MOLECULAR PATHOLOGY; MOOD DISORDER; NERVE PROJECTION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRESYNAPTIC POTENTIAL; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SIGNAL TRANSDUCTION;

EID: 84876431471     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00055     Document Type: Review

References (373)

1. Abad, N. H., Doulatabad, N. S., Mohammadi, A. and Srazi, H. R. (2011). Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case report. Iran J Psychiatry 6, 161-163.
2. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B. and Laruelle, M. (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J Psychiatry 155, 761-767.
3. Abi-Dargham, A., Laruelle, M., Aghajanian, G. K., Charney, D. and Krystal, J. (1997). The role of serotonin in the pathophysiology and treatment of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 9, 1-17.
4. Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D. R., Keilp, J., Kochan, L., Van Heertum, R., Gorman, J. M. and Laruelle, M. (2002). Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708-3719.
5. Adler, L. E., Hoffer, L. J., Griffith, J., Waldo, M. C. and Freedman, R. (1992). Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol. Psychiatry 32, 607-616.
6. Akbarian, S., Sucher, N. J., Bradley, D., Tafazzoli, A., Trinh, D., Hetrick, W. P., Potkin, S. G., Sandman, C. A., Bunney, W. E., Jr. and Jones, E. G. (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16, 19-30.
7. Albanese, A., Altavista, M. C. and Rossi, P. (1986). Organization of central nervous system dopaminergic pathways. JNeural Transm. Suppl 22, 3-17.
8. Albanese, A. and Minciacchi, D. (1983). Organization of the ascending projections from the ventral tegmental area: a multiple fluorescent retrograde tracer study in the rat. J. Comp. Neurol. 216, 406-420.
9. Allen, T. G. J., Abogadie, F. C. and Brown, D. A. (2006). Simultaneous release of glutamate and acetylcholine from single magnocellular cholinergic basal forebrain neurons. J. Neurosci. 1588-1595.
10. Anderson, J. J., Kuo, S. and Chase, T. N. (1994). Endogenous excitatory amino acids tonically stimulate striatal acetlycholine release through NMDA but not AMPA receptors. Neurosci. Lett. 176, 264-268.
11. Aosaki, T., Kimura, M. and Graybiel, A. M. (1995). Temporal and spatial characteristics of tonically active neurons of the primate's striatum. J. Neurophysiol. 73, 1234-1252.
12. Atzori, M., Kanold, P. O., Pineda, J. C., Flores-Hernandez, J. and Paz, R. D. (2005). Dopamine prevents muscarinic-induced decrease of glutamate release in the auditory cortex. Neuroscience 134, 1153-1165.
13. Auning, E., Rongve, A., Fladby, T., Booij, J., Hortobígyi, T., Siepel, F. J., Ballard, C. and Aarsland, D. (2011). Early and Presenting Symptoms of Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders 32, 202-208.
14. Azam, L., Winzer-Serhan, U. and Leslie, F. M. (2003). Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons. Neuroscience 119, 965-977.
15. Azmitia, E. C. and Segal, M. (1978). An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 179, 641-667.
16. Baghdoyan, H. A., Lydic, R. and Fleegal, M. A. (1998). M2 muscarinic autoreceptors modulate acetylcholine release in the medial pontine reticular formation. J. Pharmacol. Exp. Ther. 286, 1446-1452.
17. Banigan, M. G., Kao, P. F., Kozubek, J. A., Winslow, A. R., Medina, J., Costa, J., Schmitt, A., Schneider, A., Cabral, H., Cagsal-Getkin, O., Vanderburg, C. R. and Delalle, I. (2013). Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder Patients. PloS one 8, e48814.
18. Barnard, E. A., Skolnick, P., Olsen, R. W., Mohler, H., Sieghart, W., Biggio, G., Braestrup, C., Bateson, A. N. and Langer, S. Z. (1998). International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50, 291-313.
19. Barnes, N. M., Andrade, R., Bockaert, J., Butler, A., Hamon, M., Hensler, J., Herrick-Davis, K., Hoyer, D., Maroteaux, L., Martin, G. R., Peters, J. A., Roth, B., Sharp, T., Villalon, C. M. and Neumaier, J. (2012). 5-Hydroxytryptamine receptors, introductory chapter. IUPHAR database (IUPHAR-DB)
20. Batel, P., Houchi, H., Daoust, M., Ramoz, N., Naassila, M. and Gorwood, P. (2008). A haplotype of the DRD1 gene is associated with alcohol dependence. Alcohol Clin. Exp. Res. 32, 567572.
21. Becquet, D., Faudon, M. and Hery, F. (1988). In vivo evidence for acetylcholine control of serotonin release in the cat caudate nucleus: influence of halothane anaesthesia. Neuroscience 819-826.
22. Bencherif, M., Lippiello, P. M., Lucas, R. and Marrero, M. B. (2011). Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. CellMol. Life Sci. 68, 931-949.
23. Bendor, J., Lizardi-Ortiz, J. E., Westphalen, R. I., Brandstetter, M., Hemmings, H. C., Jr., Sulzer, D., Flajolet, M. and Greengard, P. (2010). AGAP1/AP-3-dependent endocytic recycling of M5 muscarinic receptors promotes dopamine release. The EMBO journal 29, 2813-2826.
24. Benes, F. M., Khan, Y., Vincent, S. L. and Wickramasinghe, R. (1996a). Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 22, 338-349.
25. Benes, F. M., Lim, B., Matzilevich, D., Walsh, J. P., Subburaju, S. and Minns, M. (2007). Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci U S A 104, 10164-10169.
26. Benes, F. M., McSparren, J., Bird, E. D., SanGiovanni, J. P. and Vincent, S. L. (1991). Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48, 996-1001.
27. Benes, F. M., Vincent, S. L., Alsterberg, G., Bird, E. D. and SanGiovanni, J. P. (1992). Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12, 924-929.
28. Benes, F. M., Vincent, S. L., Marie, A. and Khan, Y. (1996b). Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75, 1021-1031.
29. Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E. and Meador-Woodruff, J. H. (2007). Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32, 1888-1902.
30. Bennett, B. D. and Wilson, C. J. (1999). Spontaneous activity of neostriatal cholinergic interneurons in vitro. J. Neurosci, 19, 5586-5596.
31. Benueniste, M., Wilhelm, J., Dingledine, R. J. and Mott, D. D. (2010). Subunit-dependent modulation of kainate receptors by muscarinic acetylcholine receptors. Brain Res. 1352, 61-69.
32. Benwell, M. E. M. and Balfour, D. J. (1994). "Comparison of the effects of constant nicotine infusion on nucleus accumbens and stratal dopamine responses to acute nicotine" in The Effects of Nicotine on Biological Systems II, eds P. B. S. Clarke, M. Quik, K. Thurau, F. Aldkofer (Basel, Birkauser Verlag), 66.
33. Bernard, V., Normand, E. and Bloch, B. (1992). Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 12, 3591-3600.
34. Bertorelli, R. and Consolo, S. (1990). D1 and D2 dopaminergic regulation of acetylcholine release from striata of freely moving rats. J. Neurochem. 56, 2145-2148.
35. Bettler, B., Bowery, N. G., Cryan, J. F., Enna, S. J., Farb, D. H., Foestl, W., Kaupmann, K. and Pin, J. -P. (2012). GABAB receptors, introductory chapter. IUPHAR database (IUPHAR-DB)
36. Bianchi, C., Ferraro, L., Tanganelli, S., Morari, M., Spalluto, G., Simonato, M. and Beani, L. (1995). 5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slices. Br J Pharmacol 116, 2724-2728.
37. Bianchi, C., Siniscalchi, A. and Beani, L. (1990). 5-HT1A agonists increase and 5-HT3 agonists decrease acetylcholine efflux from the cerebral cortex of freely-moving guinea-pigs. Br. J Pharmacol. 101, 448-452.
38. Bianchi, M., Ferrario, P., Clavenna, A. and Panerai, A. E. (1997). Interleukin-6 affects scopolamine-induced amnesia, but not brain amino acid levels in mice. Neuroreport 8, 1775-1778.
39. Bjoerke-Bertheussen, J., Ehrt, U., Rongve, A., Ballard, C. and Aarsland, D. (2012). Neuropsychiatric Symptoms in Mild Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders 34, 1-6.
40. Blum, B. P. and Mann, J. J. (2002). The GABAergic system in schizophrenia. Int. J. Neuropsychopharmacol 5, 159-179.
41. Bonsi, P., Cuomo, D., Ding, J., Sciamanna, G., Ulrich, S., Tscherter, A., Bernardi, G., Surmeier, D. J. and Pisani, A. (2007). Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology 32, 1840-1854.
42. Bontempi, B., Whelan, K. T., Risbrough, V. B., Rao, T. S., Buccafusco, J. J., Lloyd, G. K. and Menzaghi, F. (2001). SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effects on working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther. 299, 297-306.
43. Brown, J. H. and Taylor, P. (1996). "Muscarinic receptor agonists and antagonists" in Goodman & Gilman's The Pharmacological Basis of Therapeutics, eds J. G. Hardman, L. E. Limbird (New York, McGraw-Hill), 141-160.
44. Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M. and McMahon, R. P. (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 165, 82-89.
45. Buchanan, R. W., Summerfelt, A., Tek, C. and Gold, J. (2003). An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr. Res. 59, 29-33.
46. Buhot, M. C., Martin, S. and Segu, L. (2000). Role of serotonin in memory impairment. Ann. Med. 32, 210-221.
47. Burnet, P. W., Eastwood, S. L. and Harrison, P. J. (1997). [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem. Int. 30, 565-574.
48. Butcher, A. J., Torrecilla, I., Young, K. W., Kong, K. C., Mistry, S. C., Bottrill, A. R. and Tobin, A. B. (2009). N-Methyl-D-aspartate Receptors Mediate the Phosphorylation and Desensitization of Muscarinic Receptors in Cerebellar Granule Neurons. J. Biol. Chem. 284, 17147-17156.
49. Butcher, L. L. and Woolf, N. J. (1984). "Histochemical distribution of acetylcholinesterase in the central nervous system: Clues to the localization of cholinergic neurons" in Handbook of Chemical Neuroanatomy, Volume 3: Classical Transmitters and Transmitter Receptors in the CNS, Part II, eds A. Bjorkland, T. Hokfelt, M. J. Kuhar (Amsterdam, Elsevier), 1-50.
50. Bymaster, F. P., Wong, D. T., Mitch, C. H., Ward, J. S., Calligaro, D. O., Schoepp, D. D., Shannon, H. E., Sheardown, M. J., Olesen, P. H. and Suzdak, P. D. (1994). Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 269, 282-289.
51. Cannon, D. M., Carson, R. E., Nugent, A. C., Eckelman, W. C., Kiesewetter, D. O., Williams, J., Rollis, D., Drevets, M., Gandhi, S., Solorio, G. and Drevets, W. C. (2006). Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 63, 741-747.
52. Carlsson, A. (1974). Antipsychotic drugs and catecholamine synapses. JPsychiatr Res 11, 57-64.
53. Carlsson, A. (1988). The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186.
54. Carlsson, A., Hansson, L. O., Waters, N. and Carlsson, M. L. (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci. 61, 75-94.
55. Carnevale, D., De, S. R. and Minghetti, L. (2007). Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS. Neurol. Disord. Drug Targets. 6, 388-397.
56. Castner, S. A., Williams, G. V. and Goldman-Rakic, P. S. (2000). Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020-2022.
57. Challiss, R. A. J. and Tobin, A. B. (2009). Acetylcholine receptors (muscarinic), introductory chapter. IUPHAR database (IUPHAR-DB)
58. Chang, B., Daniele, C. A., Gallagher, K., Madonia, M., Mitchum, R. D., Barrett, L., Vezina, P. and McGehee, D. S. (2011). Nicotinic excitation of serotonergic projections from dorsal raphe to the nucleus accumbens. J. Neurophysiol. 106, 801-808.
59. Consolo, S., Girotti, P., Russi, G. and Di Chiara, G. (1992). Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum. J. Neurochem, 59, 1555-1557.
60. Corrigall, W. A. (1999). Nicotine self-administration in animals as a dependence model. Nicotine Tob Res 1, 11-20.
61. Corrigall, W. A., Franklin, K. B., Coen, K. M. and Clarke, P. B. (1992). The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107, 285-289.
62. Cortes, R., Probst, A. and Palacios, J. M. (1984). Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: Brainstem. Neuroscience 12, 1003-1026.
63. Costello, R. W., Jacoby, D. B. and Fryer, A. D. (1998). Pulmonary neuronal M2 muscarinic receptor function in asthma and animal models of hyperreactivity. Thorax 53, 613-616.
64. Couturier, S., Bertrand, D., Matter, J. M., Hernandez, M. C., Bertrand, S., Millar, N., Valera, S., Barkas, T. and Ballivet, M. (1990). A neuronal nicotinic acetylcholine receptor subunit (a7) is developmentally regulated and forms a homo-oligomeric channel blocked by aBTX. Neuron 5, 847-856.
65. Creese, I., Burt, D. R. and Snyder, S. H. (1976). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
66. Cruz, D. A., Eggan, S. M., Azmitia, E. C. and Lewis, D. A. (2004). Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am J Psychiatry 161, 739-742.
67. Cucchiaro, G., Chaijale, N. and Commons, K. G. (2005). The Dorsal Raphe Nucleus as a Site of Action of the Antinociceptive and Behavioral Effects of the (34 Nicotinic Receptor Agonist Epibatidine. J Pharmacol Exp Ther 313, 389-394.
68. Curley, A. A., Arion, D., Volk, D. W., Asafu-Adjei, J. K., Sampson, A. R., Fish, K. N. and Lewis, D. A. (2011). Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am J Psychiatry 168, 921-929.
69. Dale, H. H. (1914). The action of certain esters and ethers of choline and their relation to muscarine. J Pharmacol Exp Ther 6, 147-190.
70. Damsma, G., Day, J. and Fibiger, H. C. (1989). Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens. Eur. J Pharmacol 186, 363-368.
71. Damsma, G., Robertson, G. S., Tham, C. S. and Fibiger, H. C. (1991). Dopaminergic regulation of striatal acetylcholine release: importance of D1 and N-methyl-D-aspartate receptors. The J Pharmacol Exp Ther 259, 1064-1072.
72. Damsma, G., Tham, C. S., Robertson, G. S. and Fibiger, H. C. (1990). Dopamine D1 receptor stimulation increases striatal acetylcholine release in the rat. Eur. J Pharmacol. 186, 335-338.
73. Dasari, S. and Gulledge, A. T. (2011). M1 and M4 Receptors Modulate Hippocampal Pyramidal Neurons. J. Neurophysiol. 105, 779-792.
74. De Klippel, N., Sarre, S., Ebinger, G. and Michotte, Y. (1993). Effect of M1-and M2-muscarinic drugs on striatal dopamine release and metabolism: an in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats. Brain Res. 630, 57-64.
75. de Paulis, T. (2001). M-100907 (Aventis). Curr. Opin. Investig. Drugs 2, 123-132.
76. Dean, B. (2003). The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J. Neurochem. 85, 1-13.
77. Dean, B. (2011). Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int. J. Neuropsychopharmacol. 14, 997-1012.
78. Dean, B., Gibbons A. S., Tawadros, N., Brooks, L., Everall, I. P. and Scarr, E. (2012). Different changes in cortical tumour necrosis factor-related pathways in schizophrenia and mood disorders. Mol Psychiatry doi:10. 1038/mp. 2012.95
79. Dean, B., Hussain, T., Hayes, W., Scarr, E., Kitsoulis, S., Hill, C., Opeskin, K. and Copolov, D. L. (1999a). Changes in serotonin2A and GABA(A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. JNeurochem 72, 1593-1599.
80. Dean, B., Pavey, G., McLeod, M., Opeskin, K., Keks, N. and Copolov, D. (2001). A change in the density of [H-3]flumazenil, but not [H-3]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. J. Affect. Disord. 66, 147-158.
81. Dean, B., Pavey, G., Scarr, E., Goeringer, K. and Copolov, D. L. (2004). Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia. Life Sci 74, 3115-3131.
82. Dean, B., Pavey, G., Thomas, D. and Scarr, E. (2006). Cortical serotonin7, 1D and 1F receptors: effects of schizophrenia, suicide and antipsychotic drug treatment. Schizophr. Res. 88, 265-274.
83. Dean, B., Tawadros, N., Scarr, E. and Gibbons, A. S. (2010). Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. J. Affect. Disord. 120, 245-248.
84. Dean, B., Tomaskovic-Crook, E., Opeskin, K., Keks, N. and Copolov, D. (1999b). No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem. Int. 34, 109-115.
85. Decker, M. W. and McGaugh, J. L. (1991). The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse 7, 151-168.
86. Del Arco, A., Segovia, G. and Mora, F. (2008). Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity. Psychopharmacology 201, 325-338.
87. Deng, C. and Huang, X. F. (2006). Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res 168, 587-590.
88. Deutch, A. Y., Clark, W. A. and Roth, R. H. (1990). Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res 521, 311-315.
89. Di Chiara, G., Carboni, E., Morelli, M., Cozzolino, A., Tanda, G. L., Pinna, A., Russi, G. and Consolo, S. (1993). Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry. Neuroscience 55, 451-456.
90. DiFiglia, M., Pasik, P. and Pasik, T. (1976). A Golgi study of neuronal types in the neostriatum of monkeys. Brain Res 114, 245-256.
91. Dilsaver, S. C. (1986). Cholinergic mechanisms in depression. Brain Res. 396, 285-316.
92. Dingledine, R., Borges, K., Bowie, D. and Traynelis, S. F. (1999). The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61.
93. Dracheva, S., Elhakem, S. L., McGurk, S. R., Davis, K. L. and Haroutunian, V. (2004). GAD67 and GAD65 mRNA and protein expression in cerebrocortical regions of elderly patients with schizophrenia. J Neurosci Res 76, 581-592.
94. Dracheva, S., Marras, S. A., Elhakem, S. L., Kramer, F. R., Davis, K. L. and Haroutunian, V. (2001). N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158, 1400-1410.
95. Drevets, W. C. and Furey, M. L. (2010). Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol. Psychiatry 67, 432-438.
96. Drevets, W. C., Zarate, J. and Furey, M. L. (2012). Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review. Biol. Psychiatry doi:10. 1016/j. biopsych.2012.09.031,
97. Duffy, A. M., Fitzgerald, M. L., Chan, J., Robinson, D. C., Milner, T. A., Mackie, K. and Pickel, V. M. (2011). Acetylcholine alpha7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex. Synapse 65, 1350-1367.
98. Dwivedi, Y. (2011). Evidence demonstrating role of microRNAs in the etiopathology of major depression. J Chem Neuroanat 42, 142-156.
99. Dyer, M. A., Freudenreich, O., Culhane, M. A., Pachas, G. N., Deckersbach, T., Murphy, E., Goff, D. C. and Evins, A. E. (2008). High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr. Res. 102, 88-95.
100. Emilien, G., Maloteaux, J. M., Geurts, M., Hoogenberg, K. and Cragg, S. (1999). Dopamine receptors--physiological understanding to therapeutic intervention potential. Pharmacol Ther 84, 133-156.
101. Everitt, B. J. and Robbins, T. W. (1997). Central Cholinergic Systems and Cognition. Ann Rev Psychology 48, 649-684.
102. Fahn, S., Burke, R. and Stern, Y. (1990). Antimuscarinic drugs in the treatment of movement disorders. Prog Brain Res 84, 389-397.
103. Fatemi, S. H., Stary, J. M., Earle, J. A., Araghi-Niknam, M. and Eagan, E. (2005). GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 72, 109-122.
104. Felten, D. L. and Shetty, A. N. (2010). Netter's Atlas of Neuroscience. 2, Saunders; Elsevier, Philapdelphia. v-438.
105. File, S. E., Kenny, P. J. and Cheeta, S. (2000). The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol. Biochem. Behav. 66, 65-72.
106. Fisahn, A., Yamada, M., Duttaroy, A., Gan, J. W., Deng, C. X., McBain, C. J. and Wess, J. (2002). Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron 33, 615-624.
107. Fisher, J. L., Pidoplichko, V. I. and Dani, J. A. (1998). Nicotine modifies the activity of ventral tegmental area dopaminergic neurons and hippocampal GABAergic neurons. J Physiol Paris 92, 209-213.
108. Forster, G. L., Yeomans, J. S., Takeuchi, J. and Blaha, C. D. (2002). M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J Neurosci 22, RC190.
109. Fournier, G. N., Materi, L. M., Semba, K. and Rasmusson, D. D. (2004). Cortical acetylcholine release and electroencephalogram activation evoked by ionotropic glutamate receptor agonists in the rat basal forebrain. Neuroscience 123, 785-792.
110. Francis, P. T. and Perry, E. K. (2007). Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord. 22, S351-S357.
111. Frank, E., Newell, K. A. and Huang, X. F. (2011). Density of metabotropic glutamate receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not differ with schizophrenia diagnosis but decreases with age. Schizophr. Res. 128, 56-60.
112. Freedman, R., Hall, M., Adler, L. E. and Leonard, S. (1995). Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 38, 22-33.
113. Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., Kutnick, J., Pender, V., Martin, L. F., Stevens, K. E., Wagner, B. D., Zerbe, G. O., Soti, F. and Kem, W. R. (2008). Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia. Am J Psychiatry 165, 1040-1047.
114. Friedman, J. I. (2004). Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacol (Berl) 174, 45-53.
115. Fryer, A. D., Adamko, D. J., Yost, B. L. and Jacoby, D. B. (1999). Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung. Life Sci. 64, 449-455.
116. Furey, M. L. and Drevets, W. C. (2006). Antidepressant Efficacy of the Antimuscarinic Drug Scopolamine: A Randomized, Placebo-Controlled Clinical Trial. Arch Gen Psychiatry 63, 1121-1129.
117. Gahring, L. C., Days, E. L., Kaasch, T., Gonzalez de, M. M., Owen, L., Persiyanov, K. and Rogers, S. W. (2005). Pro-inflammatory cytokines modify neuronal nicotinic acetylcholine receptor assembly. J. Neuroimmunol. 166, 88-101.
118. Galindo-Charles, L., Hernandez-Lopez, S., Galarraga, E., Tapia, D., Bargas, J., Garduno, J., Frias-Dominguez, C., Drucker-Colin, R. and Mihailescu, S. (2008). Serotoninergic dorsal raphe neurons possess functional postsynaptic nicotinic acetylcholine receptors. Synapse 62, 601-615.
119. Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B. and Tamminga, C. A. (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. Am. J. Psychiat. 157, 1141-1149.
120. Garbett, K., Gal-Chis, R., Gaszner, G., Lewis, D. A. and Mirnics, K. (2008). Transcriptome alterations in the prefrontal cortex of subjects with schizophrenia who committed suicide. Neuropsychopharmacol Hung. 10, 9-14.
121. Gerber, D. J., Sotnikova, T. D., Gainetdinov, R. R., Huang, S. Y., Caron, M. G. and Tonegawa, S. (2001). Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci USA 98, 15312-15317.
122. Gerfen, C. R. and Surmeier, D. J. (2011). Modulation of striatal projection systems by dopamine. Annu. Rev. Neurosci. 34, 441-466.
123. Gershon, S. and Shaw, F. H. (1961). Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet 1, 1371-1374.
124. Geyer, M. A., Puerto, A., Dawsey, W. J., Knapp, S., Bullard, W. P. and Mandell, A. J. (1976). Histologic and enzymatic studies of the mesolimbic and mesostriatal serotonergic pathways. Brain Res. 106, 241-256.
125. Gibbons, A. S., Scarr, E., Boer, S., Money, T., Jeon, W. J., Felder, C. and Dean, B. (2012). Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int. JNeuropsychopharmacol. doi:10. 1017/S1461145712000028, 1-10.
126. Gibbons, A. S., Scarr, E., McLean, C., Sundram, S. and Dean, B. (2009a). Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J. Affect. Disord. 116, 184-191.
127. Gibbons, A. S., Scarr, E., McLean, C., Sundram, S. and Dean, B. (2009b). Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J. Affect. Disord. 116, 184-191.
128. Giebelen, I. A., van Westerloo, D. J., Larosa, G. J., de Vos, A. F. and van der Poll, T. (2007). Stimulation of alpha 7 cholinergic receptors inhibits lipopolysaccharide-induced neutrophil recruitment by a tumor necrosis factor alpha-independent mechanism. Shock 27, 443-447.
129. Goldman-Rakic, P. S., Castner, S. A., Svensson, T. H., Siever, L. J. and Williams, G. V. (2004). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacol Berl 174, 3-16.
130. Goldman-Rakic, P. S., Muly, E. C., III and Williams, G. V. (2000). D(1) receptors in prefrontal cells and circuits. Brain Res Rev 31, 295-301.
131. Gomeza, J., Shannon, H., Kostenis, E., Felder, C., Zhang, L., Brodkin, J., Grinberg, A., Sheng, H. and Wess, J. (1999a). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96, 1692-1697.
132. Gomeza, J., Zhang, L., Kostenis, E., Felder, C., Bymaster, F., Brodkin, J., Shannon, H., Xia, B., Deng, C. and Wess, J. (1999b). Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96, 10483-10488.
133. Gonzalez-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., Lopez-Gimenez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J. and Sealfon, S. C. (2008). Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452, 93-97.
134. Graveland, G. A., Williams, R. S. and DiFiglia, M. (1985). A Golgi study of the human neostriatum: neurons and afferent fibers. J Comp Neurol 234, 317-333.
135. Gray, L., Scarr, E. and Dean, B. (2006). Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res. 143, 111-120.
136. Gray, N. S., Pilowsky, L. S., Gray, J. A. and Kerwin, R. W. (1995). Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr Res 17, 95-107.
137. Graybiel, A. M. (1990). Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13, 244-254.
138. Grilli, M., Summa, M., Salamone, A., Olivero, G., Zappettini, S., Di Prisco, S., Feligioni, M., Usai, C., Pittaluga, A. and Marchi, M. (2012). In vitro exposure to nicotine induces endocytosis of presynaptic AMPA receptors modulating dopamine release in rat nucleus accumbens nerve terminals. Neuropharmacol 63, 916-926.
139. Grilli, M., Zappettini, S., Raiteri, L. and Marchi, M. (2009). Nicotinic and muscarinic cholinergic receptors coexist on GABAergic nerve endings in the mouse striatum and interact in modulating GABA release. Neuropharmacol 56, 610-614.
140. Grishin, A. A., Benquet, P. and Gerber, U. (2005). Muscarinic receptor stimulation reduces NMDA responses in CA3 hippocampal pyramidal cells via Ca2+-dependent activation of tyrosine phosphatase. Neuropharmacol 49, 328-337.
141. Grishin, A. A., Gee, C. E., Gerber, U. and Benquet, P. (2004). Differential calcium-dependent modulation of NMDA currents in CA1 and CA3 hippocampal pyramidal cells. J. Neurosci. 24, 350-355.
142. Gu, Z. and Yakel, J. (2011). Timing-Dependent Septal Cholinergic Induction of Dynamic Hippocampal Synaptic Plasticity. Neuron 71, 155-165.
143. Guidotti, A., Auta, J., Davis, J. M., Di-Giorgi-Gerevini, V., Dwivedi, Y., Grayson, D. R., Impagnatiello, F., Pandey, G., Pesold, C., Sharma, R., Uzunov, D. and Costa, E. (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57, 1061-1069.
144. Guillin, O., Abi-Dargham, A. and Laruelle, M. (2007). Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78, 1-39.
145. Guo, J. D., Hazra, R., Dabrowska, J., Muly, E. C., Wess, J. and Rainnie, D. G. (2012). Presynaptic muscarinic M-2 receptors modulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuropharmacol 62, 1671-1683.
146. Haddad, E. B., Rousell, J., Lindsay, M. A. and Barnes, P. J. (1996). Synergy between tumor necrosis factor alpha and interleukin 1beta in inducing transcriptional down-regulation of muscarinic M2 receptor gene expression. Involvement of protein kinase A and ceramide pathways. J. Biol. Chem. 271, 32586-32592.
147. Hakak, Y., Walker, J. R., Li, C., Wong, W. H., Davis, K. L., Buxbaum, J. D., Haroutunian, V. and Fienberg, A. A. (2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98, 4746-4751.
148. Hamam, B. N., Sinai, M., Poirier, G. and Chapman, C. A. (2007). Cholinergic suppression of excitatory synaptic responses in Layer II of the medial entorhinal cortex. Hippocampus 17, 103-113.
149. Hamilton, S. E., Loose, M. D., Qi, M., Levey, A. I., Hille, B., McKnight, G. S., Idzerda, R. L. and Nathanson, N. M. (1997). Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 94, 13311-13316.
150. Hanada, S., Mita, T., Nishino, N. and Tanaka, C. (1987). [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 1987/01/19, 259-266.
151. Hanisch, U. K. (2002). Microglia as a source and target of cytokines. Glia 40, 140-155.
152. Hashimoto, T., Nishino, N., Nakai, H. and Tanaka, C. (1991). Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci. 48, 355-363.
153. Healy, D. J., Haroutunian, V., Powchik, P., Davidson, M., Davis, K. L., Watson, S. J. and Meador-Woodruff, J. H. (1998). AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacol 19, 278-286.
154. Heckers, S. and Konradi, C. (2010). Hippocampal pathology in schizophrenia. Curr Top Behav Neurosci 2011/02/12, 529-553.
155. Hersch, S. M., Gutekunst, C. A., Rees, H. D., Heilman, C. J. and Levey, A. I. (1994). Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 14, 3351-3363.
156. Hettinger, J. A., Liu, X., Schwartz, C. E., Michaelis, R. C. and Holden, J. J. (2008). A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. Am J Med Genet B Neuropsychiatr. Genet 147B, 628-636.
157. Hilmas, C., Pereira, E. F., Alkondon, M., Rassoulpour, A., Schwarcz, R. and Albuquerque, E. X. (2001). The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21, 7463-7473.
158. Hollander, E., Mohs, R. C. and Davis, K. L. (1986). Cholinergic approaches to the treatment of alzheimer's disease. Brit Med Bull 42, 97-100.
159. Holt, D. J., Herman, M. M., Hyde, T. M., Kleinman, J. E., Sinton, C. M., German, D. C., Hersh, L. B., Graybiel, A. M. and Saper, C. B. (1999). Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 94, 21-31.
160. Hornung, J. P. (2003). The human raphe nuclei and the serotonergic system. J Chem Neuroanat 26, 331-343.
161. Hornykiewicz, O. (1981). "Brain neurotransmitter changes in Parkinson's disease" in Movement Disorders eds. Marsden, D. C. & Fahn, S. (London, UK: Butterworth) 41-58.
162. Hoyer, D. and Middlemiss, D. N. (1989). Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci 10, 130-132.
163. Hrdina, P. D. and Du, L. (2001). Levels of serotonin receptor 2A higher in suicide victims? Am J Psychiatry 158, 147-148.
164. Huang, W. and Li, M. D. (2009). Differential allelic expression of dopamine D1 receptor gene (DRD1) is modulated by microRNA miR-504. Biol Psychiatry 65, 702-705.
165. Huang, W., Ma, J. Z., Payne, T. J., Beuten, J., Dupont, R. T. and Li, M. D. (2008). Significant association of DRD1 with nicotine dependence. Hum Genet 123, 133-140.
166. Hwang, J., Hwang, H., Lee, H. W. and Suk, K. (2010). Microglia signaling as a target of donepezil. Neuropharmacol 58, 1122-1129.
167. Hyland, N. P. and Cryan, J. F. (2010). A Gut Feeling about GABA: Focus on GABA(B) Receptors. Front Pharmacol 2010/01/01, 124
168. Ichikawa, J., Chung, Y. C., Li, Z., Dai, J. and Meltzer, H. Y. (2002). Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res 958, 176-184.
169. Impagnatiello, F., Guidotti, A. R., Pesold, C., Dwivedi, Y., Caruncho, H., Pisu, M. G., Uzunov, D. P., Smalheiser, N. R., Davis, J. M., Pandey, G. N., Pappas, G. D., Tueting, P., Sharma, R. P. and Costa, E. (1998). A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 95, 15718-15723.
170. Imperato, A., Mulas, A. and Di Chiara, G. (1986). Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132, 337-338.
171. Ishida, K., Murata, M., Kato, M., Utsunomiya, I., Hoshi, K. and Taguchi, K. (2005). Beta-phenylethylamine stimulates striatal acetylcholine release through activation of the AMPA glutamatergic pathway. Biol Pharm Bull 28, 1626-1629.
172. Ishikawa, M., Mizukami, K., Iwakiri, M. and Asada, T. (2005). Immunohistochemical and immunoblot analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Neurosci Lett 383, 272-277.
173. Ishikawa, M., Mizukami, K., Iwakiri, M., Hidaka, S. and Asada, T. (2004). GABAA receptor gamma subunits in the prefrontal cortex of patients with schizophrenia and bipolar disorder. Neuroreport 15, 1809-1812.
174. Izzo, P. N. and Bolam, J. P. (1988). Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat. J Comp Neurol 269, 219-234.
175. Javoy, F., Euvrard, C., Herbet, A. and Glowinski, J. (1977). Involvement of the dopamine nigrostriatal system in the picrotoxin effect on striatal acetylcholine levels. Brain Res 126, 382-386.
176. Johnson, D. E., Drummond, E., Grimwood, S., Sawant-Basak, A., Miller, E., Tseng, E., McDowell, L. L., Vanase-Frawley, M. A., Fisher, K. E., Rubitski, D. M., Stutzman-Engwall, K. J., Nelson, R. T., Gorczyca, R. R., Hajos, M. and Siok, C. J. (2012). The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal e oscillations. J Pharmacol Exp Ther 341, 681-691.
177. Johnston, G. A. (2005). GABA(A) receptor channel pharmacology. Curr Pharm Des 2005/06/25, 1867-1885.
178. Jones, C. K., Byun, N. and Bubser, M. (2012). Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia. Neuropsychopharmacol 37, 16-42.
179. Joyce, J. N., Shane, A., Lexow, N., Winokur, A., Casanova, M. F. and Kleinman, J. E. (1993). Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics [see comments]. Neuropsychopharmacol 8, 315-336.
180. Kalen, P. and Wiklund, L. (1989). Projections from the medial septum and diagonal band of Broca to the dorsal and central superior raphe nuclei: a non-cholinergic pathway. Exp. Brain Res. 75, 401-416.
181. Kamsler, A., McHugh, T. J., Gerber, D., Huang, S. Y. and Tonegawa, S. (2010). Presynaptic m1 muscarinic receptors are necessary for mGluR long-term depression in the hippocampus. Proc. Natl. Acad. Sci. U. S. A. 107, 1618-1623.
182. Kapur, S. and Remington, G. (2001). Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50, 873-883.
183. Karlsson, P., Farde, L., Halldin, C. and Sedvall, G. (2002). PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159, 761-767.
184. Karreman, M. and Moghaddam, B. (1996). The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 66, 589-598.
185. Katsu, H. (2001). Selective 5-HT1A receptor agonist, 8-OH-DPAT, locally administered into the dorsal raphe nucleus increased extracellular acetylcholine concentrations in the medial prefrontal cortex of conscious rats. Nihon Shinkei Seishin Yakurigaku Zasshi 21, 121-123.
186. Kawamata, J. and Shimohama, S. (2011). Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J. Alzheimers. Dis. 24 Suppl 2, 95-109.
187. Kayadjanian, N., Retaux, S., Menetrey, A. and Besson, M. J. (1994). Stimulation by nicotine of the spontaneous release of [3H]gamma-aminobutyric acid in the substantia nigra and in the globus pallidus of the rat. Brain Res 649, 129-135.
188. Keefe, R. S., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murthy, A., Sovel, M., Li, C. and Goldman, R. (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacol 33, 1217-1228.
189. Kehr, J., Hu, X. J., Yoshitake, T., Wang, F. H., Osborne, P., Stenfors, C. and Ogren, S. 0. (2010). The selective 5-HT(1A) receptor antagonist NAD-299 increases acetylcholine release but not extracellular glutamate levels in the frontal cortex and hippocampus of awake rat. Eur. Neuropsychopharmacol. 20, 487-500.
190. Kenny, P. J., File, S. E. and Neal, M. J. (2000). Evidence for a complex influence of nicotinic acetylcholine receptors on hippocampal serotonin release. J Neurochem. 75, 2409-2414.
191. Khateb, A., Fort, P., Alonso, A., Jones, B. E. and Mulethaler, M. (1993). Pharmacological and Immunohistochemical Evidence for Serotonergic Modulation of Cholinergic Nucleus Basalis Neurons. Eur J Neurosci 5, 541-547.
192. Kia, H. K., Brisorgueil, M. J., Daval, G., Langlois, X., Hamon, M. and Verge, D. (1996). Serotonin1A receptors are expressed by a subpopulation of cholinergic neurons in the rat medial septum and diagonal band of Broca--a double immunocytochemical study. Neuroscience 74, 143-154.
193. Klein, J. C., Eggers, C., Kalbe, E., Weisenbach, S., Hohmann, C., Vollmar, S., Baudrexel, S., Diederich, N. J., Heiss, W. D. and Hilker, R. (2010). Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 74, 885-892.
194. Klempan, T. A., Sequeira, A., Canetti, L., Lalovic, A., Ernst, C., ffrench-Mullen, J. and Turecki, G. (2009). Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 14, 175-189.
195. Knable, M. B. and Weinberger, D. R. (1997). Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11, 123-131.
196. Koike, H., Fukumoto, K., Iijima, M. and Chaki, S. (2013). Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 238, 48-52.
197. Kolachana, B. S., Saunders, R. C. and Weinberger, D. R. (1995). Augmentation of prefrontal cortical monoaminergic activity inhibits dopamine release in the caudate nucleus: an in vivo neurochemical assessment in the rhesus monkey. Neuroscience 69, 859-868.
198. Koos, T. and Tepper, J. M. (2002). Dual cholinergic control of fast-spiking interneurons in the neostriatum. J Neurosci 22, 529-535.
199. Koyama, Y. and Kayama, Y. (1993). Mutual interactions among cholinergic, noradrenergic and serotonergic neurons studied by ionophoresis of these transmitters in rat brainstem nuclei. Neuroscience 55, 1117-1126.
200. Ladinsky, H., Consolo, S., Bianchi, S. and Jori, A. (1976). Increase in striatal acetylcholine by picrotoxin in the rat: evidence for a gabergic-dopaminergic-cholinergic link. Brain Res 108, 351-361.
201. Lahti, A. C., Weiler, M. A., Michaelidis, T., Parwani, A. and Tamminga, C. A. (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacol 25, 455-467.
202. Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., Baldwin, R. M., Seibyl, J. P., Krystal, J. H., Charney, D. S. and Innis, R. B. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93, 9235-9240.
203. Lazaris, A., Bertrand, F., Lazarus, C., Galani, R., Stemmelin, J., Poirier, R., Kelche, C. and Cassel, J. C. (2003). Baseline and 8-OH-DPAT-induced release of acetylcholine in the hippocampus of aged rats with different levels of cognitive dysfunction. Brain Res. 967, 181-190.
204. Le Moal, M. and Simon, H. (1991). Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 71, 155-234.
205. Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M. and Christopoulos, A. (2010). Molecular mechanisms of action and in vivo validation of an m(4) muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacol 35, 855-869.
206. Lee, T., Seeman, P., Tourtellotte, W. W., Farley, I. J. and Hornykeiwicz, O. (1978). Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains. Nature 274, 897-900.
207. Lena, C., Changeux, J. P. and Mulle, C. (1993). Evidence for preterminal nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J Neurosci 13, 2680-2688.
208. Lester, D. B., Rogers, T. D. and Blaha, C. D. (2010). Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16, 137-162.
209. Levin, E. D., McGurk, S. R., Rose, J. E. and Butcher, L. L. (1989). Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY 171555. Pharmacol Biochem Behav 33, 919-922.
210. Lewis, D. A., Cho, R. Y., Carter, C. S., Eklund, K., Forster, S., Kelly, M. A. and Montrose, D. (2008). Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 165, 1585-1593.
211. Li, D. P. and Pan, H. L. (2001). Potentiation of glutamatergic synaptic input to supraoptic neurons by presynaptic nicotinic receptors. Am. J. Physiol. -Regul. Integr. Comp. Physiol. 281, R1105-R1113.
212. Li, J., Mathieu, S. L., Harris, R., Ji, J., Anderson, D. J., Malysz, J., Bunnelle, W. H., Waring, J. F., Marsh, K. C., Murtaza, A., 0lson, L. M. and Gopalakrishnan, M. (2011). Role of alpha7 nicotinic acetylcholine receptors in regulating tumor necrosis factor-alpha (TNF-alpha) as revealed by subtype selective agonists. J. Neuroimmunol. 239, 37-43.
213. Lieberman, J. A., Dunbar, G., Segreti, A. C., Girgis, R. R., Seoane, F., Beaver, J. S., Duan, N. and Hosford, D. A. (2013). A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia. Neuropsychopharmacol doi: 10.1038/npp.2012.259.
214. Lu, W. Y., Xiong, Z. G., Lei, S., 0rser, B. A., Dudek, E., Browning, M. D. and MacDonald, J. F. (1999). G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nature Neurosci 2, 331-338.
215. Lucas-Meunier, E., Fossier, P., Baux, G. and Amar, M. (2003). Cholinergic modulation of the cortical neuronal network. Pflugers Archiv Eur J Physiol 446, 17-29.
216. Ma, Z., Strecker, R. E., McKenna, J. T., Thakkar, M. M., McCarley, R. W. and Tao, R. (2005). Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats. Neuroscience 135, 949-958.
217. Mackay, A. V., Bird, E. D., Spokes, E. G., Rossor, M., Iversen, L. L., Creese, I. and Snyder, S. H. (1980). Dopamine receptors and schizophrenia: drug effect or illness? Lancet 2, 915-916.
218. Mackay, A. V., Iversen, L. L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I. and Synder, S. H. (1982). Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39, 991-997.
219. Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G. and Manji, H. K. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349-352.
220. Mahmoodi, G., Ahmadi, S., Pourmotabbed, A., Oryan, S. and Zarrindast, M. R. (2010). Inhibitory avoidance memory deficit induced by scopolamine: Interaction of cholinergic and glutamatergic systems in the ventral tegmental area. Neurobiol. Learn. Mem. 94, 83-90.
221. Mancama, D., Arranz, M. J., Landau, S. and Kerwin, R. (2003). Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119, 2-6.
222. Mansour, A. and Watson, S. J. (1995). "Dopamine Receptor Expression in the Central Nervous System" in Psychopharmacology-The Fourth Generation of Progress eds. Bloom, F. E. & Kupfer, D. J. (New York, NY; Raven Press) 19.
223. Marchi, M., Bocchieri, P., Garbarino, L. and Raiteri, M. (1989). Muscarinic inhibition of endogenous glutamate release from rat hippocapmus synaptosomes. Neurosci Lett 96, 229-234.
224. Marchi, M., Sanguineti, P. and Raiteri, M. (1990). Muscarinic receptors mediate direct inhibition of GABA release from rat striatal nerve terminals. Neurosci Lett 116, 347-351.
225. Marcos, B., Gil-Bea, F. J., Hirst, W. D., Garcia-Alloza, M. and Ramirez, M. J. (2006). Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci 24, 1299-1306.
226. Maris, R. W. (2002). Suicide. The Lancet 360, 319-326.
227. Marshall, D. L., Redfern, P. H. and Wonnacott, S. (1997). Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68, 1511-1519.
228. Martin-Ruiz, C. M., Haroutunian, V. H., Long, P., Young, A. H., Davis, K. L., Perry, E. K. and Court JA (2003). Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54, 1222-1233.
229. Marzella, P. L., Hill, C., Keks, N., Singh, B. and Copolov, D. (1997). The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia. Biol Psychiatry 42, 648-654.
230. Matsui, M., Motomura, D., Karasawa, H., Fujikawa, T., Jiang, J., Komiya, Y., Takahashi, S. and Taketo, M. M. (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 97, 9579-9584.
231. Maura, G., Fedele, E. and Raiteri, M. (1989). Acetylcholine release from rat hippocampal slices is modulated by 5-hydroxytryptamine. Eur J Pharmacol. 165, 173-179.
232. McCullumsmith, R. E., Kristiansen, L. V., Beneyto, M., Scarr, E., Dean, B. and Meador-Woodruff, J. H. (2007). Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res. 1127, 108-118.
233. McGurk, S. R., Levin, E. D. and Butcher, L. L. (1988). Cholinergic-dopaminergic interactions in radial-arm maze performance. Behav Neural Biol 49, 234-239.
234. McGurk, S. R., Levin, E. D. and Butcher, L. L. (1989). Radial-arm maze performance in rats is impaired by a combination of nicotinic-cholinergic and D2 dopaminergic antagonist drugs. 99, Psychopharmacol (Berl) 371-373.
235. Meltzer, H. Y. (1995). Role of Serotonin in the Action of Atypical Antipsychotic Drugs. J. Clin. Neuroscience. 3, 64-75.
236. Mifsud, J. C., Hernandez, L. and Hoebel, B. G. (1989). Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 478, 365-367.
237. Millan, M. J., Gobert, A., Roux, S., Porsolt, R., Meneses, A., Carli, M., Di, C. B., Jaffard, R., Rivet, J. M., Lestage, P., Mocaer, E., Peglion, J. L. and Dekeyne, A. (2004). The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. JPharmacol. Exp. Ther. 311, 190-203.
238. Millar, N. S., Gotti, C., Marks, M. J. and Wonnacott, S. (2011). Nicotinic acetylcholine receptors, introductory chapter. IUPHAR database (IUPHAR-DB)
239. Miller, A. D. and Blaha, C. D. (2005). Midbrain muscarinic receptor mechanisms underlying regulation of mesoaccumbens and nigrostriatal dopaminergic transmission in the rat. Eur J Neurosci 21, 1837-1846.
240. Mita, T., Hanada, S., Nishino, N., Kuno, T., Nakai, H., Yamadori, T., Mizoi, Y. and Tanaka, C. (1986). Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21, 1407-1414.
241. Miyakawa, T., Yamada, M., Duttaroy, A. and Wess, J. (2001). Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 21, 5239-5250.
242. Mizukami, K., Ishikawa, M., Hidaka, S., Iwakiri, M., Sasaki, M. and Iritani, S. (2002). Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatry 26, 393-396.
243. Mizukami, K., Sasaki, M., Ishikawa, M., Iwakiri, M., Hidaka, S., Shiraishi, H. and Iritani, S. (2000). Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia. Neurosci Lett 283, 101-104.
244. Morilak, D. A. and Ciaranello, R. D. (1993). 5-HT2 receptor immunoreactivity on cholinergic neurons of the pontomesencephalic tegmentum shown by double immunofluorescence. Brain Res. 627, 49-54.
245. Myers, T. A., Kaushal, D. and Philipp, M. T. (2009). Microglia are mediators of Borrelia burgdorferi-induced apoptosis in SH-SY5Y neuronal cells. PLoS. Pathog. 5, e1000659-
246. Nair, S. G. and Gudelsky, G. A. (2004). Activation of 5-HT2 receptors enhances the release of acetylcholine in the prefrontal cortex and hippocampus of the rat. Synapse 53, 202-207.
247. Nakamura, M. and Jang, I. S. (2012). Muscarinic M4 receptors regulate GABAergic transmission in rat tuberomammillary nucleus neurons. Neuropharm 63, 936-944.
248. Nakamura, S., Goshima, Y., Yue, J. L., Miyamae, T. and Misu, Y. (1992). Transmitter-like 3, 4-dihydroxyphenylalanine is tonically released by nicotine in striata of conscious rats. Eur J Pharmacol 222, 75-80.
249. Navakkode, S. and Korte, M. (2012). Cooperation between cholinergic and glutamatergic receptors are essential to induce BDNF-dependent long-lasting memory storage. Hippocampus 22, 335-346.
250. Nelson, C. L., Sarter, M. and Bruno, J. P. (2005). Prefrontal cortical modulation of acetylcholine release in posterior parietal cortex. Neuroscience 132, 347-359.
251. Newell, K. A., Zavitsanou, K., Jew, S. K. and Huang, X. F. (2007). Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 225-233.
252. Nie, Z., Scott, G. D., Weis, P. D., Itakura, A., Fryer, A. D. and Jacoby, D. B. (2011). Role of TNF-alpha in virus-induced airway hyperresponsiveness and neuronal M(2) muscarinic receptor dysfunction. Br. J. Pharmacol. 164, 444-452.
253. Nirogi, R., Jabaris, S. L., Jayarajan, P., Abraham, R., Shanmuganathan, D., Rasheed, M. A., Royapalley, P. K. and Goura, V. (2011). Antinociceptive activity of alpha4beta2 neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. Eur. J. Pharmacol. 668, 155-162.
254. Nisell, M., Nomikos, G. G., Hertel, P. and Svensson, T. H. (1994). "Acute nicotine administration differentially affects mesolimbic and mesocortical dopamine activity" in The Effects of Nicotine on Biological Systems II eds. Clarke, P. B. S., Quik, M., Thurau, K. & Adkolfer, F. (Basel; Birkauser Verlag) 74.
255. Nisell, M., Nomikos, G. G. and Svensson, T. H. (1994b). Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75, 348-352.
256. Nisell, M., Nomikos, G. G. and Svensson, T. H. (1995). Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76, 157-162.
257. Niswender, C. M. and Conn, P. J. (2010). Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease. Ann. Rev. Pharmacol. Toxicol. 50, 295-322.
258. Noback, C. R., Ruggerio, D. A., Demarest, R. J. and Strominger, N. L. (2005). "Reticular Formation and Limbic System" in The human nervous system: Structure and function eds. Noback, C. R., Ruggerio, D. A., Demarest, R. J. and Strominger, N. L. (New Jersey; Humana Press) 387-405.
259. Noga, J. T., Hyde, T. M., Bachus, S. E., Herman, M. M. and Kleinman, J. E. (2001). AMPA receptor binding in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophr. Res. 48, 361-363.
260. Noga, J. T. and Wang, H. (2002). Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse 45, 250-258.
261. Ohtsuki, T., Ishiguro, H., Detera-Wadleigh, S. D., Toyota, T., Shimizu, H., Yamada, K., Yoshitsugu, K., Hattori, E., Yoshikawa, T. and Arinami, T. (2002). Association between serotonin 4 receptor gene polymorphisms and bipolar disorder in Japanese case-control samples and the NIMH Genetics Initiative Bipolar Pedigrees. Mol. Psychiatry 7, 954-961.
262. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., Iyo, M., Tateno, Y. and Toru, M. (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636.
263. Olianas, M. C., Adem, A., Karlsson, E. and Onali, P. (1996). Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3). Br J Pharmacol 118, 283-288.
264. Olianas, M. C. and 0nali, P. (1996). Antagonism of striatal muscarinic receptors inhibiting dopamine D1 receptor-stimulated adenylyl cyclase activity by cholinoceptor antagonist used to treat Parkinson's disease. Br J Pharmacol 118, 827-828.
265. Olszewski, J. and Baxter, D. (1954). Cytoarchitecture of the human brainstem. By Jerzy Olszewski and Donald Baxter. J. Comp. Neurol. 101, 825-825.
266. Pandey, G. N., Dwivedi, Y., Rizavi, H. S., Ren, X., Pandey, S. C., Pesold, C., Roberts, R. C., Conley, R. R. and Tamminga, C. A. (2002). Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159, 419-429.
267. Park, J. Y. and Spruston, N. (2012). Synergistic Actions of Metabotropic Acetylcholine and Glutamate Receptors on the Excitability of Hippocampal CA1 Pyramidal Neurons. J. Neurosci. 32, 6081-6091.
268. Patel, S. S., Attard, A., Jacobsen, P. and Shergill, S. (2010). Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report. BMC Psychiatry 10, 68
269. Pavlov, V. A., 0chani, M., Gallowitsch-Puerta, M., 0chani, K., Huston, J. M., Czura, C. J., Al-Abed, Y. and Tracey, K. J. (2006). Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc Natl Acad Sci USA 103, 5219-5223.
270. Pavlov, V. A. and Tracey, K. J. (2006). Controlling inflammation: the cholinergic antiinflammatory pathway. Biochem Soc Trans. 34, 1037-1040.
271. Paylor, R., Nguyen, M., Crawley, J. N., Patrick, J., Beaudet, A. and Orr-Urtreger, A. (1998). α7 Nicotinic Receptor Subunits Are Not Necessary for Hippocampal-Dependent Learning or Sensorimotor Gating: A Behavioral Characterization of Acra7-Deficient Mice. Learning & Memory 5, 302-316.
272. Pena, G., Cai, B., Ramos, L., Vida, G., Deitch, E. A. and Ulloa, L. (2011). Cholinergic regulatory lymphocytes re-establish neuromodulation of innate immune responses in sepsis. J. Immunol. 187, 718-725.
273. Perl, O., Ilani, T., Strous, R. D., Lapidus, R. and Fuchs, S. (2003). The alpha7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes. FASEB J 17, 1948-1950.
274. Perry, E., Walker, M., Grace, J. and Perry, R. (1999). Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22, 273-280.
275. Petroff, O. A. and Rothman, D. L. (1998). Measuring human brain GABA in vivo: effects of GABA-transaminase inhibition with vigabatrin. Mol Neurobiol 16, 97-121.
276. Peyron, C., Petit, J. M., Rampon, C., Jouvet, M. and Luppi, P. H. (1997). Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 82, 443-468.
277. Piper, M., Beneyto, M., Burne, T. H. J., Eyles, D. W., Lewis, D. A. and McGrath, J. J. (2012). The Neurodevelopmental Hypothesis of Schizophrenia: Convergent Clues from Epidemiology and Neuropathology. Psychiatric Clinics of North America 35, 571-584.
278. Pontieri, F. E., Tanda, G., Orzi, F. and Di Chiara, G. (1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382, 255-257.
279. Porter, R. H. P., Eastwood, S. L. and Harrison, P. J. (1997). Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res. 751, 217-231.
280. Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R. and Kouassi, E. (2008). Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 63, 801-808.
281. Pycock, C. J., Kerwin, R. W. and Carter, C. J. (1980). Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 286, 74-76.
282. Radcliffe, K. A., Fisher, J. L., Gray, R. and Dani, J. A. (1999). Nicotinic modulation of glutamate and GABA synaptic transmission of hippocampal neurons. Ann N Y. AcadSci 868, 591-610.
283. Raedler, T. J., Bymaster, F. P., Tandon, R., Copolov, D. and Dean, B. (2006). Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12, 232-246.
284. Raedler, T. J., Knable, M. B., Jones, D. W., Urbina, R. A., Gorey, J. G., Lee, K. S., Egan, M. F., Coppola, R. and Weinberger, D. R. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry 160, 118-127.
285. Raiteri, M., Leardi, R. and Marchi, M. (1984). Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J Pharmacol Exp Ther 228, 209-214.
286. Razani-Boroujerdi, S., Behl, M., Hahn, F. F., Pena-Philippides, J. C., Hutt, J. and Sopori, M. L. (2008). Role of muscarinic receptors in the regulation of immune and inflammatory responses. J. Neuroimmunol. 194, 83-88.
287. Reuben, M. and Clarke, P. B. S. (2000). Nicotine-evoked [3H]5-hydroxytryptamine release from rat striatal synaptosomes. Neuropharmacol 39, 290-299.
288. Reynolds, G. P., Riederer, P., Jellinger, K. and Gabriel, E. (1981). Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacol 20, 1319-1320.
289. Reynolds, L. M. and Reynolds, G. P. (2011). Differential regional N-acetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. J. Psychiatr. Res. 45, 54-59.
290. Ribeiro, E. B., Bettiker, R. L., Bogdanov, M. and Wurtman, R. J. (1993). Effects of systemic nicotine on serotonin release in rat brain. Brain Res. 621, 311-318.
291. Roda, E., Coccini, T., Acerbi, D., Castoldi, A., Bernocchi, G. and Manzo, L. (2008). Cerebellum cholinergic muscarinic receptor (subtype-2 and-3) and cytoarchitecture after developmental exposure to methylmercury: an immunohistochemical study in rat. J. Chem. Neuroanat. 35, 285-294.
292. Rowntree, D. W., Nevin, S. and Wilson, A. (1950). The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol. Neurosurg. Psychiatry 13, 47-62.
293. Rutz, S., Riegert, C., Rothmaier, A. K., Buhot, M. C., Cassel, J. C. and Jackisch, R. (2006). Presynaptic serotonergic modulation of 5-HT and acetylcholine release in the hippocampus and the cortex of 5-HT1B-receptor knockout mice. Brain Res. Bull. 70, 81-93.
294. Sales, M. E. (2010). Muscarinic receptors as targets for anti-inflammatory therapy. Curr. Opin. Investig. Drugs 11, 1239-1245.
295. Scarr, E. (2012). Muscarinic Receptors: Their Roles in Disorders of the Central Nervous System and Potential as Therapeutic Targets. CNS. Neurosci. Ther. 18, 369-379.
296. Scarr, E., Beneyto, M., Meador-Woodruff, J. H. and Dean, B. (2005). Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacol 30, 1521-1531.
297. Scarr, E., Cowie, T. F., Kanellakis, S., Sundram, S., Pantelis, C. and Dean, B. (2009). Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia. Mol Psychiatry 14, 1017-1023.
298. Scarr, E. and Dean, B. (2008). Muscarinic receptors: Do they have a role in the pathology of schizophrenia? J. Ne^^^oche^. 107, 1188-1195.
299. Scarr, E. and Dean, B. (2009). Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert. Rev Neurother. 9, 73-86.
300. Scarr, E., Pavey, G., Copolov, D. and Dean, B. (2004). Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. Schizophr. Res. 71, 383-392.
301. Scarr, E., Sundram, S., Keriakous, D. and Dean, B. (2007). Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol. Psychiatry 61, 1161-1170.
302. Scatton, B. and Bartholini, G. (1982). gamma-Aminobutyric acid (GABA) receptor stimulation. IV. Effect of progabide (SL 76002) and other GABAergic agents on acetylcholine turnover in rat brain areas. J Pharmacol Exp Ther 220, 689-695.
303. Schechter, L. E., Smith, D. L., Rosenzweig-Lipson, S., Sukoff, S. J., Dawson, L. A., Marquis, K., Jones, D., Piesla, M., Andree, T., Nawoschik, S., Harder, J. A., Womack, M. D., Buccafusco, J., Terry, A. V., Hoebel, B., Rada, P., Kelly, M., Abou-Gharbia, M., Barrett, J. E. and Childers, W. (2005). Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. JPharmacol. Exp. Ther. 314, 1274-1289.
304. Schetz, J. A. (2009). Dopamine receptors, introductory chapter. IUPHAR database (IUPHAR-DB)
305. Schoffelmeer, A. N., Van Vliet, B. J., Wardeh, G. and Mulder, A. H. (1986). Muscarine receptor-mediated modulation of [3H]dopamine and [14C]acetylcholine release from rat neostriatal slices: selective antagonism by gallamine but not pirenzepine. Eur J Pharmacol 128, 291-294.
306. Schwarcz, R., Bruno, J. P., Muchowski, P. J. and Wu, H. Q. (2012). Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13, 465-477.
307. Seeman, P., Guan, H. C. and Van Tol, H. H. (1993). Dopamine D4 receptors elevated in schizophrenia. Nature 365, 441-445.
308. Seeman, P., Lee, T., Chau-Wong, M. and Wong, K. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
309. Semba, K., Reiner, P. B., McGeer, E. G. and Fibiger, H. C. (1988). Brainstem afferents to the magnocellular basal forebrain studied by axonal transport, immunohistochemistry, and electrophysiology in the rat. J. Comp. Neurol. 267, 433-453.
310. Severance, E. G. and Yolken, R. H. (2008). Novel alpha7 nicotinic receptor isoforms and deficient cholinergic transcription in schizophrenia. Genes Brain Behav. 7, 37-45.
311. Sharman, J. L., Mpamhanga, C. P., Spedding, M., Germain, P., Staels, B., Dacquet, C., Laudet, V. and Harmar, A. J. (2011). IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res. 39, D534-D538.
312. Shytle, R. D., Mori, T., Townsend, K., Vendrame, M., Sun, N., Zeng, J., Ehrhart, J., Silver, A. A., Sanberg, P. R. and Tan, J. (2004). Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89, 337-343.
313. Sigurdsson, E., Fombonne, E., Sayal, K. and Checkley, S. (1999). Neurodevelopmental antecedents of early-onset bipolar affective disorder. Br J Psychiatry 174, 121-127.
314. Smolders, I., Bogaert, L., Ebinger, G. and Michotte, Y. (1997). Muscarinic modulation of striatal dopamine, glutamate, and GABA release, as measured with in vivo microdialysis. J Neurochem 68, 1942-1948.
315. Stanley, M. and Mann, J. J. (1983). Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1, 214-216.
316. Steidl, S., Miller, A. D., Blaha, C. D. and Yeomans, J. S. (2011). M(5) muscarinic receptors mediate striatal dopamine activation by ventral tegmental morphine and pedunculopontine stimulation in mice. PloS one 2011/11/22, e27538
317. Steiger, J. L. and Russek, S. J. (2004). GABAA receptors: building the bridge between subunit mRNAs, their promoters, and cognate transcription factors. Pharmacol Ther 101, 259-281.
318. Steinbusch, H. W. (1981). Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience 6, 557-618.
319. Sugita, S., Uchimura, N., Jiang, Z. G. and North, R. A. (1991). Distinct muscarinic receptors inhibit release of gamma-aminobutyric acid and excitatory amino acids in mammalian brain. Proc Natl Acad Sci USA 88, 2608-2611.
320. Sullivan, M. A., Chen, H. and Morikawa, H. (2008). Recurrent inhibitory network among striatal cholinergic interneurons. J Neurosci 28, 8682-8690.
321. Sumiyoshi, T., Stockmeier, C. A., 0verholser, J. C., Thompson, P. A. and Meltzer, H. Y. (1995). Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 681, 109-116.
322. Sun, H., Kennedy, P. J. and Nestler, E. J. (2013). Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacol 38, 124-137.
323. Tanaka, S., Matsunaga, H., Kimura, M., Tatsumi, K., Hidaka, Y., Takano, T., Uema, T., Takeda, M. and Amino, N. (2003). Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 141, 155-164.
324. Tandon, R. and Greden, J. F. (1989). Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 46, 745-753.
325. Tauscher, J., Kapur, S., Verhoeff, N. P., Hussey, D. F., Daskalakis, Z. J., Tauscher-Wisniewski, S., Wilson, A. A., Houle, S., Kasper, S. and Zipursky, R. B. (2002). Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 59, 514-520.
326. Tepper, J. M., Tecuapetla, F., Koos, T. and Ibanez-Sandoval, O. (2010). Heterogeneity and diversity of striatal GABAergic interneurons. Front Neuroanat. 4, 150
327. Thompson, M., Weickert, C. S., Wyatt, E. and Webster, M. J. (2009). Decreased glutamic acid decarboxylase(67) mRNA expression in multiple brain areas of patients with schizophrenia and mood disorders. J Psychiatr Res 43, 970-977.
328. Thomsen, M. S., Weyn, A. and Mikkelsen, J. D. (2011). Hippocampal +|7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disorders 13, 701-707.
329. Threlfell, S., Clements, M. A., Khodai, T., Pienaar, I. S., Exley, R., Wess, J. and Cragg, S. J. (2010). Striatal muscarinic receptors promote activity dependence of dopamine transmission via distinct receptor subtypes on cholinergic interneurons in ventral versus dorsal striatum. J. Neurosci 30, 3398-3408.
330. Toro, C. and Deakin, J. F. (2005). NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80, 323-330.
331. Toth, E., Sershen, H., Hashim, A., Vizi, E. S. and Lajtha, A. (1992). Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid. Neurochem Res 17, 265-271.
332. Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H. J., Myers, S. J. and Dingledine, R. (2010). Glutamate Receptor Ion Channels: Structure, Regulation, and Function. Pharmacol. Rev. 62, 405-496.
333. Tucci, S. A., Genn, R. F. and File, S. E. (2003). Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of +|7 receptors. Neuropharmacol 44, 367-373.
334. Turner, J., Hughes, L. F. and Toth, L. A. (2010). Sleep, activity, temperature and arousal responses of mice deficient for muscarinic receptor M2 or M4. Life Sci. 86, 158-169.
335. Tyagi, E., Agrawal, R., Nath, C. and Shukla, R. (2010). Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem. Int. 56, 135-142.
336. Tzschentke, T. M. (2001). Pharmacology and behavioral pharmacology of the mesocortical dopamine system. ProgNeurobiol 63, 241-320.
337. van Elst, L. T., Valerius, G., Buchert, M., Thiel, T., Rusch, N., Bubl, E., Hennig, J., Ebert, D. and Olbrich, H. M. (2005). Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 58, 724-730.
338. Verbout, N. G. and Jacoby, D. B. (2012). Muscarinic receptor agonists and antagonists: effects on inflammation and immunity. Handb. Exp. Pharmacol. 208, 403-427.
339. Vinson, P. N. and Conn, P. J. (2012). Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacol 62, 1461-1472.
340. Volk, D., Austin, M., Pierri, J., Sampson, A. and Lewis, D. (2001). GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 158, 256-265.
341. Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R. and Lewis, D. A. (2000). Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch Gen Psychiatry 57, 237-245.
342. Volk, D. W., Eggan, S. M. and Lewis, D. A. (2010). Alterations in Metabotropic Glutamate Receptor 1 alpha and Regulator of G Protein Signaling 4 in the Prefrontal Cortex in Schizophrenia. Am J Psychiatry 167, 1489-1498.
343. Volk, D. W., Pierri, J. N., Fritschy, J. M., Auh, S., Sampson, A. R. and Lewis, D. A. (2002). Reciprocal alterations in pre-and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb. Cortex 12, 1063-1070.
344. Wang, D., Noda, Y., Zhou, Y., Nitta, A., Furukawa, H. and Nabeshima, T. (2007). Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. Neuropharmacol 53, 379-389.
345. Wang, H., Ng, K., Hayes, D., Gao, X., Forster, G., Blaha, C. and Yeomans, J. (2004). Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. Neuropsychopharmacol 29, 2126-2139.
346. Weiner, D. M., Levey, A. I. and Brann, M. R. (1990). Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc Natl Acad Sci USA 87, 7050-7054.
347. Wess, J. (2012). "Novel Muscarinic Receptor Mutant Mouse Models". In Muscarinic receptors eds Fryer, A. D., Christopoulos, A. and Nathanson, N. M. (Heidleberg; Springer Berlin) 95-117.
348. West, P. J., Marcy, V. R., Marino, M. J. and Schaffhauser, H. (2009). Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 164, 692-701.
349. Whiting, P. J. (2003). GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today 8, 445-450.
350. Wilkinson, L. S. (1997). The nature of interactions involving prefrontal and striatal dopamine systems. J Psychopharmacol 11, 143-150.
351. Wilson, M. A. and Molliver, M. E. (1991). The organization of serotonergic projections to cerebral cortex in primates: regional distribution of axon terminals. Neuroscience 44, 537-553.
352. Witten, I. B., Lin, S. C., Brodsky, M., Prakash, R., Diester, I., Anikeeva, P., Gradinaru, V., Ramakrishnan, C. and Deisseroth, K. (2010). Cholinergic Interneurons Control Local Circuit Activity and Cocaine Conditioning. Science 330, 1677-1681.
353. Wonnacott, S., Barik, J., Dickinson, J. and Jones, I. W. (2006). Nicotinic receptors modulate transmitter cross talk in the CNS: nicotinic modulation of transmitters. J Mol Neurosci 30, 137-140.
354. Woo, T. U., Shrestha, K., Amstrong, C., Minns, M. M., Walsh, J. P. and Benes, F. M. (2007). Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder. Schizophr Res 2007/08/19, 46-61.
355. Woo, T. U., Walsh, J. P. and Benes, F. M. (2004). Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 2004/07/09, 649-657.
356. Wooley, D. W. and Shaw, E. (1954). A biological and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA 40, 228-231.
357. Woolf, N. J. (1991). Cholinergic systems in mammalian brain and spinal cord. ProgNeurobiol 37, 475-524.
358. Woolf, N. J. and Butcher, L. L. (1989). Cholinergic systems in the rat brain: IV. descending projections of the pontomesencephalic tegmentum. Brain Res Bull 23, 519-540.
359. Xu, Z. P., Yang, K., Xu, G. N., Zhu, L., Hou, L. N., Zhang, W. H., Chen, H. Z. and Cui, Y. Y. (2012). Role of M3 mAChR in in vivo and in vitro models of LPS-induced inflammatory response. Int. Immunopharmacol. 14, 320-327.
360. Yamada, M., Basile, A. S., Fedorova, I., Zhang, W., Duttaroy, A., Cui, Y., Lamping, K. G., Faraci, F. M., Deng, C. X. and Wess, J. (2003). Novel insights into M5 muscarinic acetylcholine receptor function by the use of gene targeting technology. Life Sci 74, 345-353.
361. Yamada, M., Lamping, K. G., Duttaroy, A., Zhang, W., Cui, Y., Bymaster, F. P., McKinzie, D. L., Felder, C. C., Deng, C. X., Faraci, F. M. and Wess, J. (2001a). Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 98, 14096-14101.
362. Yamada, M., Miyakawa, T., Duttaroy, A., Yamanaka, A., Moriguchi, T., Makita, R., Ogawa, M., Chou, C. J., Xia, B., Crawley, J. N., Felder, C. C., Deng, C. X. and Wess, J. (2001b). Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410, 207-212.
363. Yasuda, R. P., Ciesla, W., Flores, L. R., Wall, S. J., Li, M., Satkus, S. A., Weisstein, J. S., Spagnola, B. V. and Wolfe, B. B. (1993). Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Molecular Pharmacol 43, 149-157.
364. Yeomans, J. S. (1995). Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacol 12, 3-16.
365. Zarei, M. M., Radcliffe, K. A., Chen, D., Patrick, J. W. and Dani, J. A. (1999). Distributions of nicotinic acetylcholine receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Neuroscience 88, 755-764.
366. Zavitsanou, K., Katsifis, A., Mattner, F. and Xu-Feng, H. (2004). Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacol 29, 619-625.
367. Zhang, L., McLarnon, J. G., Goghari, V., Lee, Y. B., Kim, S. U. and Krieger, C. (1998). Cholinergic agonists increase intracellular Ca2+ in cultured human microglia. Neurosci. Lett. 255, 33-36.
368. Zhang, L. M. and Warren, R. A. (2002). Muscarinic and nicotinic presynaptic modulation of EPSCs in the nucleus accumbens during postnatal development. J. Neurophysiol. 88, 3315-3330.
369. Zhang, W., Yamada, M., Gomeza, J., Basile, A. S. and Wess, J. (2002). Multiple muscarinic acetylcholine receptor subtypes modulate striatal dopamine release, as studied with M1-M5 muscarinic receptor knock-out mice. J. Neurosci. 22, 6347-6352.
370. Zhao, C., Wang, F., Pun, F. W., Mei, L., Ren, L., Yu, Z., Ng, S. K., Chen, J., Tsang, S. Y. and Xue, H. (2012). Epigenetic regulation on GABRB2 isoforms expression: Developmental variations and disruptions in psychotic disorders. Schizophr Res 134, 260-266.
371. Zheng, F. and Johnson, S. W. (2003). Metabotropic glutamate and muscarinic cholinergic receptor-mediated preferential inhibition of N-methyl-D-aspartate component of transmissions in rat ventral tegmental area. Neuroscience 116, 1013-1020.
372. Zhou, F. M., Liang, Y. and Dani, J. A. (2001). Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 4, 1224-1229.
373. Zilles, K., Werner, L., Qü, M., Schleicher, A. and Gross, G. (1991). Quantitative auto radiography of 11 different transmitter binding sites in the basal forebrain region of the rat-Evidence of heterogeneity in distribution patterns. Neuroscience 42, 473-481.